Leflunomide Reduces Proliferation and Induces Apoptosis in Neuroblastoma Cells In Vitro and In Vivo

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Zhu, Shunqin ^a   Yan, Xiaomin ^a   Xiang, Zhonghuai ^a   Ding, Han Fei ^b   Cui, Hongjuan ^a  

^a SOUTHWEST UNIVERSITY   (China)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDROOROTATE DEHYDROGENASE; LEFLUNOMIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NEUROBLASTOMA; NEUROBLASTOMA CELL; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; S PHASE CELL CYCLE CHECKPOINT; TUMOR CELL LINE; TUMOR XENOGRAFT;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DOWN-REGULATION; HUMANS; ISOXAZOLES; MICE; MICE, SCID; NEUROBLASTOMA; OXIDOREDUCTASES ACTING ON CH-CH GROUP DONORS; S PHASE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84881237756     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0071555     Document Type: Article

References (31)

1. Brodeur GM, (2003) Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 3: 203-216.
2. Beckwith JB, Martin RF, (1968) Observations on the histopathology of neuroblastomas. J Pediatr Surg 3: 106-110.
3. Pardo N, Marti F, Fraga G, Illa J, Badell I, et al. (1996) High-dose systemic interleukin-2 therapy in stage IV neuroblastoma for one year after autologous bone marrow transplantation: pilot study. Med Pediatr Oncol 27: 534-539.
4. Couzin-Frankel J, (2011) Personalized medicine. Pushing the envelope in neuroblastoma therapy. Science 333: 1569-1571.
5. Arakaki TL, Buckner FS, Gillespie JR, Malmquist NA, Phillips MA, et al. (2008) Characterization of Trypanosoma brucei dihydroorotate dehydrogenase as a possible drug target; structural, kinetic and RNAi studies. Mol Microbiol 68: 37-50.
6. Evans DR, Guy HI, (2004) Mammalian pyrimidine biosynthesis: fresh insights into an ancient pathway. J Biol Chem 279: 33035-33038.
7. Nara T, Hshimoto T, Aoki T, (2000) Evolutionary implications of the mosaic pyrimidine-biosynthetic pathway in eukaryotes. Gene 257: 209-222.
8. Teschner S, Burst V, (2010) Leflunomide: a drug with a potential beyond rheumatology. Immunotherapy 2: 637-650.
9. Greene S, Watanabe K, Braatz-Trulson J, Lou L, (1995) Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflunomide. Biochem Pharmacol 50: 861-867.
10. Bruneau JM, Yea CM, Spinella-Jaegle S, Fudali C, Woodward K, et al. (1998) Purification of human dihydro-orotate dehydrogenase and its inhibition by A77 1726, the active metabolite of leflunomide. Biochem J 336 (Pt 2): 299-303.
11. Xu X, Williams JW, Gong H, Finnegan A, Chong AS, (1996) Two activities of the immunosuppressive metabolite of leflunomide, A77 1726. Inhibition of pyrimidine nucleotide synthesis and protein tyrosine phosphorylation. Biochem Pharmacol 52: 527-534.
12. Xu X, Shen J, Mall JW, Myers JA, Huang W, et al. (1999) In vitro and in vivo antitumor activity of a novel immunomodulatory drug, leflunomide: mechanisms of action. Biochem Pharmacol 58: 1405-1413.
13. Chen SF, Ruben RL, Dexter DL, (1986) Mechanism of action of the novel anticancer agent 6-fluoro-2-(2′-fluoro-1,1′-biphenyl-4-yl)-3-methyl-4-quinolinecarbo xylic acid sodium salt (NSC 368390): inhibition of de novo pyrimidine nucleotide biosynthesis. Cancer Res 46: 5014-5019.
14. Battiwalla M, Paplham P, Almyroudis NG, McCarthy A, Abdelhalim A, et al. (2007) Leflunomide failure to control recurrent cytomegalovirus infection in the setting of renal failure after allogeneic stem cell transplantation. Transpl Infect Dis 9: 28-32.
15. Araya CE, Garin EH, Neiberger RE, Dharnidharka VR, (2009) Leflunomide therapy for BK virus allograft nephropathy in pediatric and young adult kidney transplant recipients. Pediatr Transplant 14: 145-150.
16. Williams JW, Javaid B, Kadambi PV, Gillen D, Harland R, et al. (2005) Leflunomide for polyomavirus type BK nephropathy. N Engl J Med 352: 1157-1158.
17. Avery RK, Bolwell BJ, Yen-Lieberman B, Lurain N, Waldman WJ, et al. (2004) Use of leflunomide in an allogeneic bone marrow transplant recipient with refractory cytomegalovirus infection. Bone Marrow Transplant 34: 1071-1075.
18. Ehlert K, Groll AH, Kuehn J, Vormoor J, (2006) Treatment of refractory CMV-infection following hematopoietic stem cell transplantation with the combination of foscarnet and leflunomide. Klin Padiatr 218: 180-184.
19. Loffler M, Fairbanks LD, Zameitat E, Marinaki AM, Simmonds HA, (2005) Pyrimidine pathways in health and disease. Trends Mol Med 11: 430-437.
20. Shawver LK SD, Mann E, Chen H, Tsai J, Chu L, et al. (1997) Inhibition of platelet-derived growth factor-mediated signal transduction and tumor growth by N-[4-(trifluoromethyl)-phenyl]5-methylisoxazole-4-carboxamide. Clin Cancer Res 3: 1167-1177.
21. van der Heijden JW, Oerlemans R, Tak PP, Assaraf YG, Kraan MC, et al. (2009) Involvement of breast cancer resistance protein expression on rheumatoid arthritis synovial tissue macrophages in resistance to methotrexate and leflunomide. Arthritis Rheum 60: 669-677.
22. White RM, Cech J, Ratanasirintrawoot S, Lin CY, Rahl PB, et al. (2011) DHODH modulates transcriptional elongation in the neural crest and melanoma. Nature 471: 518-522.
23. Yong VW, Kim SU, (1987) A new double labelling immunofluorescence technique for the determination of proliferation of human astrocytes in culture. J Neurosci Methods 21: 9-16.
24. Cui H, Ma J, Ding J, Li T, Alam G, et al. (2006) Bmi-1 regulates the differentiation and clonogenic self-renewal of I-type neuroblastoma cells in a concentration-dependent manner. J Biol Chem 281: 34696-34704.
25. Baumann P, Mandl-Weber S, Volkl A, Adam C, Bumeder I, et al. (2009) Dihydroorotate dehydrogenase inhibitor A771726 (leflunomide) induces apoptosis and diminishes proliferation of multiple myeloma cells. Mol Cancer Ther 8: 366-375.
26. Ruckemann K, Fairbanks LD, Carrey EA, Hawrylowicz CM, Richards DF, et al. (1998) Leflunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated T-lymphocytes from healthy humans. J Biol Chem 273: 21682-21691.
27. Ringshausen I, Oelsner M, Bogner C, Peschel C, Decker T, (2008) The immunomodulatory drug Leflunomide inhibits cell cycle progression of B-CLL cells. Leukemia 22: 635-638.
28. Sawamukai N, Saito K, Yamaoka K, Nakayamada S, Ra C, et al. (2007) Leflunomide inhibits PDK1/Akt pathway and induces apoptosis of human mast cells. J Immunol 179: 6479-6484.
29. Dietrich S, Kramer OH, Hahn E, Schafer C, Giese T, et al. (2011) Leflunomide Induces Apoptosis in Fludarabine-Resistant and Clinically Refractory CLL Cells. Clin Cancer Res 18: 417-431.
30. Hail N Jr, Chen P, Bushman LR, (2010) Teriflunomide (leflunomide) promotes cytostatic, antioxidant, and apoptotic effects in transformed prostate epithelial cells: evidence supporting a role for teriflunomide in prostate cancer chemoprevention. Neoplasia 12: 464-475.
31. Cherwinski HM, Cohn RG, Cheung P, Webster DJ, Xu YZ, et al. (1995) The Immunosuppressant Leflunomide Inhibits Lymphocyte-Proliferation by Inhibiting Pyrimidine Biosynthesis. Journal of Pharmacology and Experimental Therapeutics 275: 1043-1049.